Patent 8933120 was granted and assigned to Allergan, Inc. on January, 2015 by the United States Patent and Trademark Office.
A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.